Loading clinical trials...

COMPLETED

Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients

Quantification of Therapy Effects After Microsurgery, Percutaneous Irradiation and Chemotherapy by FET-PET Analysis

NCT01089868•Ludwig-Maximilians - University of Munich

Summary

The aim of this study is to establish FET-PET as an additional therapy assessment parameter in patients diagnosed with a glioblastoma multiforme receiving radiochemotherapy and adjuvant chemotherapy after previous resection or biopsy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•neuroradiologically suspected Glioblastoma multiforme
•histological verification will be obtained either by microsurgery or by stereotactic biopsy. The neuropathological diagnosis will be verified by a reference neuropathologist
•patients will undergo radiochemotherapy subsequent to surgical procedure
•patients older than 18 years
•Karnofsky Performance Score \>=70
•pregnant or nursing female patients will not be included in this study
•safe contraceptive methods during the radiochemotherapy and chemotherapy

Exclusion Criteria

•patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills
•patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan
•medical history of a metastatic brain disease
•patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.

Locations (3)

Department of Stereotactic Neurosurgery

Freiburg im Breisgau, Baden-Wurttemberg, Germany

University Hospital Munich, Department of Neurosurgery

Munich, Bavaria, Germany

University Hospital Bonn, Department of Neurosurgery

Bonn, North Rhine-Westphalia, Germany

Key Dates

Start Date

January 1, 2007

Primary Completion Date

June 1, 2011

Completion Date

July 1, 2012

Last Updated

August 7, 2012

Enrollment

ACTUAL participants

Conditions

Glioblastoma Multiforme

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512

Glioblastoma Multiforme

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients

Inclusion Criteria

Exclusion Criteria

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Targeted Pediatric High-Grade Glioma Therapy

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Study of Pembrolizumab and M032 (NSC 733972)

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma